You can buy or sell ETTX and other stocks, options, and ETFs commission-free!
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. The listed name for ETTX is Entasis Therapeutics Holdings Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Mar 26, Pre-Market